Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Schistosomiasis is a severe parasitic disease, endemic in 74 developing countries with up to 600 million people, including many children, infected and 800 million at risk of contracting the disease following infection with Schistosoma mansoni, S. haematobium or S. japonicum. Disease burden is estimated to exceed 70 million disability-adjusted life-years, and leads to remarkably high YLD (years lived with disability) rates. Even more importantly, people with schistosomiasis are highly susceptible to malaria, tuberculosis and hepatic and acquired immunodeficiency viruses. There is only one drug, praziquantel, currently available for treatment and it has high efficacy, low cost, and limited side effects. However, only 13% of the target population has received the drug, and those treated are at continuous risk of reinfection necessitating repeated drug administration and the emergence of drug resistant parasites is a constant threat. There currently is no vaccine. While the target of >40% protection has been achieved with some molecules such as excretory-secretory proteins including calpain, glyceraldehyde 3-phosphate dehydrogenase, and cysteine peptidases, very recent articles reiterate the findings published during the last 2 decades of the last century, contradicting the established data of the pioneers of schistosome biology. A consensus should be reached without delay, in order to propose collaborative independent experiments and proceed ahead to pre- and clinical trials with efficacious candidate vaccine molecules. The proposed plan aims to finally reach an objective and fruitful agreement , via inviting established and young researchers from the United States, Brazil, China, Australia, and Europe who are working with different vaccine antigens, adjuvants, and approaches for immunization against S. mansoni, S. haematobium, and S. japonicum. It is hoped that the forum will end with a very few candidate antigens and a consensus approach regarding target immune responses, thus leading to encouraging the World Health Organization and other international foundations to sponsor the development and implementation of the urgently required, yet still elusive, vaccine for preventing and eliminating the transmission of schistosomiasis.

Schistosomiasis --- Schistosoma mansoni --- Schistosoma haematobium --- Type 2 cytokines --- Vaccine --- Immune responses --- Schistosoma japonicum --- Vaccine candidates

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The impact of fat intake on hypercholesterolemia and related atherosclerotic cardiovascular diseases has been studied for decades. However, the current evidence base suggests that fatty acids also influences cardiometabolic diseases through other mechanisms including effects on glucose metabolism, body fat distribution, blood pressure, inflammation, and heart rate. Furthermore, studies evaluating single fatty acids have challenged the simplistic view of shared health effects within fatty acid groups categorized by degree of saturation. In addition, investigations of endogenous fatty acid metabolism, including genetic studies of fatty acid metabolizing enzymes, and the identification of novel metabolically derived fatty acids have further increased the complexity of fatty acids’ health impacts. This Special Issue aims to include original research and up-to-date reviews on genetic and dietary modulation of fatty acids, and the role and function of dietary and metabolically derived fatty acids in cardiometabolic health.

coronary artery disease --- n-6 fatty acids --- ischemic heart disease --- n-3 fatty acids --- body weight --- alternatively activated macrophages --- type 2 cytokines --- children --- medium-chain triglyceride --- fat --- omega-3 PUFA --- substitution models --- obesity --- EETs --- arachidonic acid --- blood pressure --- Genome-wide association study (GWAS) --- antioxidant --- Mediterranean diet --- Insulin sensitivity --- PUFA --- n-3 PUFA --- long-chain triglyceride --- fish oil --- omega 3 --- CAD --- adipose tissue --- FADS --- blood lipids --- hemodynamics --- genotype --- erucic acid --- klotho --- CYP450 eicosanoids --- cardiometabolic disease --- fibrosis --- desaturase --- EEQs --- cohort study --- lipid metabolism --- fatty acid --- metabolic disease --- epidemiology --- omega-3 --- inflammation --- docosapentaenoic acid --- omega-6 PUFA --- type 2 diabetes mellitus --- diet --- CKD --- human --- perivascular adipose tissue --- seafood --- cardiovascular disease --- prospective cohort study --- linoleic acid --- low-fat diet --- conjugated fatty acids --- furan fatty acids --- unsaturated fat --- statins --- fish --- cholesterol ester --- CHD --- COPD